Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.540
Neutral
RSI(14)
54.057
Neutral
STOCH(KDJ)(9,3,3)
44.828
Neutral
ATR(14)
1.179
High Vlolatility
CCI(14)
-40.238
Neutral
Williams %R
56.938
Sell
TRIX(12,20)
0.117
Sell
StochRSI(14)
54.358
Buy
Bristol-Myers Squibb Co
BMY55.050USD
+0.770+1.42%
Close 01/30, 16:00（ET）Quotes delayed by 15 min
112.08BMarket Cap
18.53P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bristol-Myers Squibb Co
Currency: USD Updated: 2026-01-30Key Insights
Bristol-Myers Squibb Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 15 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 56.68.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bristol-Myers Squibb Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Bristol-Myers Squibb Co Highlights
StrengthsRisks
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 18.53, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.68B shares, decreasing 0.01% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 95.85K shares of this stock.
Analyst Rating
Based on
30
analysts
Hold
Current Rating
56.916
Target Price
+4.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-30The current financial score of Bristol-Myers Squibb Co is 9.30, ranking 8 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.22B, representing a year-over-year increase of 2.77%, while its net profit experienced a year-over-year increase of 81.75%.
Score
Financials
6.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
9.75
Bristol-Myers Squibb Co's Company Valuation
Currency: USD Updated: 2026-01-30The current valuation score of Bristol-Myers Squibb Co is 8.31, ranking 22 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 18.53, which is 35.43% below the recent high of 25.09 and 192.66% above the recent low of -17.17.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 15/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-30The current earnings forecast score of Bristol-Myers Squibb Co is 6.93, ranking 125 out of 159 in the Pharmaceuticals industry. The average price target is 53.00, with a high of 68.00 and a low of 33.10.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
30
analysts
Hold
Current Rating
56.916
Target Price
+4.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Bristol-Myers Squibb Co
BMY
30
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-30The current price momentum score of Bristol-Myers Squibb Co is 8.81, ranking 34 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 57.37 and the support level at 52.39, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
54.822
Buy
MA10
54.768
Buy
MA20
55.121
Sell
MA50
52.850
Buy
MA100
49.097
Buy
MA200
48.335
Buy
Institutional Confidence
Currency: USD Updated: 2026-01-30The current institutional shareholding score of Bristol-Myers Squibb Co is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 84.73%, representing a quarter-over-quarter decrease of 0.43%. The largest institutional shareholder is The Vanguard, holding a total of 197.67M shares, representing 9.71% of shares outstanding, with 3.75% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Charles Schwab Investment Management, Inc.
JP Morgan Asset Management
Geode Capital Management, L.L.C.
Norges Bank Investment Management (NBIM)
Capital International Investors
Columbia Threadneedle Investments (US)
1
2
Risk Assessment
Currency: USD Updated: 2026-01-30The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bristol-Myers Squibb Co is 9.23, ranking 12 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.29
VaR
+2.23%
240-Day Maximum Drawdown
+32.50%
240-Day Volatility
+29.02%
Return
Best Daily Return
60 days
+5.62%
120 days
+7.09%
5 years
+11.44%
Worst Daily Return
60 days
-4.07%
120 days
-4.07%
5 years
-8.51%
Sharpe Ratio
60 days
+2.84
120 days
+1.65
5 years
+0.09
Risk Assessment
Maximum Drawdown
240 days
+32.50%
3 years
+43.94%
5 years
+51.12%
Return-to-Drawdown Ratio
240 days
+0.07
3 years
-0.13
5 years
-0.07
Skewness
240 days
-0.04
3 years
+0.57
5 years
+0.43
Volatility
Realised Volatility
240 days
+29.02%
5 years
+24.70%
Standardised True Range
240 days
+2.31%
5 years
+2.22%
Downside Risk-Adjusted Return
120 days
+316.62%
240 days
+316.62%
Maximum Daily Upside Volatility
60 days
+22.70%
Maximum Daily Downside Volatility
60 days
+20.52%
Liquidity
Average Turnover Rate
60 days
+0.62%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
-25.45%
60 days
-7.99%
120 days
-0.42%
Peer Comparison
Pharmaceuticals
Bristol-Myers Squibb Co
BMY
8.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
